Santol

Sandoricum koetjape contains koetjapic acid (KA), a seco-A-ring oleanane triterpene isolated from stem bark that induces intrinsic apoptosis, suppresses VEGF-driven angiogenesis, and downregulates Wnt, c-Myc/MAX, HIF, and MAPK/ERK signaling in colorectal cancer cells. In vitro, KA triggers mitochondrial membrane potential loss at 20 µg/mL in HCT-116 colorectal carcinoma cells and blocks HUVEC proliferation, migration, and tube formation, while methanolic peel extract achieves DPPH antioxidant IC₅₀ of 30 µg/mL.

Origin & History

Sandoricum koetjape is native to Indochina and the Malay Peninsula, with cultivation extending throughout Southeast Asia including the Philippines, Indonesia, Thailand, Cambodia, and Laos. The tree thrives in humid tropical lowland forests at elevations below 600 meters, preferring well-drained loamy soils with high rainfall. It has been cultivated for centuries as both a food crop and medicinal resource, with the stem bark, fruit flesh, and peel each exploited for distinct ethnobotanical purposes.

Historical & Cultural Context

Sandoricum koetjape has been integrated into traditional healing systems across Southeast Asia for centuries, documented in Indonesian jamu, Malaysian herbalism, Cambodian and Laotian folk medicine, and Filipino hilot practice. The stem bark is the most pharmacologically exploited part, prepared as aqueous decoctions or poultices for the management of diarrheal illness, febrile episodes, skin conditions, and pain, aligning with the anti-inflammatory and antimicrobial activities now observed in laboratory research. In the Philippines, the fruit known as santol holds cultural importance both as a commonly consumed edible fruit and as a component of traditional healing, with the glycoside sandoricoside historically referenced as a medicinally active compound. The plant's inclusion in the Meliaceae family alongside mahogany and neem underscores its phytochemical richness, and it has attracted patent activity for anti-angiogenic and anti-tumorigenic applications based on KA's molecular pharmacology.

Health Benefits

- **Anti-Colorectal Cancer Activity**: Koetjapic acid (KA) selectively inhibits HCT-116 colorectal carcinoma cell proliferation through intrinsic mitochondrial apoptosis at 20 µg/mL, with cytotoxic potency increasing in a time-dependent manner across in vitro MTT assays.
- **Anti-Angiogenic Effects**: KA suppresses vascular endothelial growth factor (VEGF) synthesis and blocks HUVEC endothelial cell proliferation, migration, and tube differentiation, disrupting tumor neovascularization pathways that are critical for solid tumor progression.
- **Anti-Inflammatory Properties**: Stem bark and fruit extracts inhibit prostaglandin E₂ (PGE₂) production and have demonstrated activity in a mouse ear inflammation model, suggesting cyclooxygenase pathway modulation by triterpene constituents including sandorinic and sentulic acids.
- **Antioxidant Capacity**: Methanolic peel extract achieves DPPH radical scavenging IC₅₀ of 30 µg/mL and ABTS IC₅₀ of 48 µg/mL, attributable to tannins, coumarins, and betacyanins concentrated in the fruit peel fraction.
- **Broad-Spectrum Cytotoxicity Against Hematological and Solid Tumors**: Secondary triterpenes sandorinic acid and sentulic acid, co-isolated from stem bark, display cytotoxicity against HL-60 myeloid leukemia, MCF-7 breast cancer, and HCT-116 colon carcinoma cell lines in vitro.
- **Antibacterial and DNA Polymerase Inhibition**: Stem bark extracts have demonstrated antibacterial activity and inhibition of DNA polymerase enzyme function, suggesting mechanistic utility against microbial pathogens consistent with traditional fever and diarrhea applications in Filipino hilot practice.
- **Traditional Gastrointestinal and Fever Relief**: Ethnobotanical use across Indonesia, Malaysia, Cambodia, and the Philippines documents stem bark decoctions for diarrhea and febrile illness, with biological plausibility supported by the anti-inflammatory and antimicrobial activities of its triterpene constituents.

How It Works

Koetjapic acid (KA), the dominant bioactive triterpene of Sandoricum koetjape stem bark, induces intrinsic apoptosis in HCT-116 colorectal carcinoma cells by causing mitochondrial membrane potential collapse at 20 µg/mL, a classic hallmark of the intrinsic caspase cascade. At the transcriptional level, KA downregulates multiple pro-proliferative oncogenic pathways including Wnt/β-catenin, c-Myc/MAX heterodimerization, hypoxia-inducible factor (HIF) signaling, and MAPK/ERK and MAPK/JNK kinase cascades, while paradoxically upregulating NF-κB at 25 µg/mL (p<0.05–0.001), an effect that may reflect a stress-response compensatory mechanism. KA simultaneously blocks VEGF biosynthesis in tumor cells and inhibits VEGF-stimulated HUVEC endothelial proliferation, migration, and capillary tube differentiation, severing angiogenic support for tumor growth. Fruit-derived tannins and saponins contribute secondary anti-proliferative and pro-apoptotic effects, while PGE₂ inhibition by bark constituents underlies the documented anti-inflammatory and antipyretic activities.

Scientific Research

The entire body of evidence for Sandoricum koetjape is confined to in vitro cell culture studies and a single mouse ear inflammation preclinical model; no human clinical trials have been identified in the published literature. Key in vitro findings include MTT-based cytotoxicity assays demonstrating KA activity in HCT-116, MCF-7, MDA-MB-231, HepG2, and HL-60 cell lines, with VEGF pathway suppression and apoptosis mechanistic studies conducted in HUVEC endothelial cells. Antioxidant characterization of methanolic fruit extracts via DPPH and ABTS assays and cytotoxicity screening of peel extracts against HT-29 colorectal adenocarcinoma and Vero normal cells have been reported, but no dose–response studies in animal tumor models or pharmacokinetic profiling in any species have been published. The evidence base is therefore considered preliminary and insufficient to support therapeutic claims in humans.

Clinical Summary

No human clinical trials exist for Sandoricum koetjape or its isolated constituent koetjapic acid. All mechanistic and efficacy data derive from in vitro studies using cancer cell lines and HUVEC endothelial cells, with a single preclinical mouse ear inflammation model. Quantified outcomes are limited to cell viability percentages (e.g., 47.39% inhibition of HT-29 at 2000 µg/mL peel extract) and antioxidant IC₅₀ values (DPPH 30 µg/mL, ABTS 48 µg/mL), none of which translate directly to human therapeutic doses. Confidence in clinically meaningful outcomes is very low; Sandoricum koetjape remains a candidate for investigational research rather than a clinically validated therapeutic agent.

Nutritional Profile

The edible fruit flesh of Sandoricum koetjape provides modest macronutrients typical of tropical fruits, including carbohydrates (primarily sugars and dietary fiber), trace proteins, and negligible fat. Micronutrient content includes vitamin C, potassium, and calcium, though precise quantified values vary by cultivar and ripeness stage and are not consistently reported in the peer-reviewed literature. Phytochemically, the peel is particularly enriched in tannins (hydrolyzable and condensed classes), coumarins, betacyanins, and saponins, which are responsible for the demonstrated antioxidant IC₅₀ of 30 µg/mL (DPPH) and 48 µg/mL (ABTS). The stem bark contains the lipophilic triterpenes koetjapic acid, sandorinic acid, and sentulic acid in concentrations sufficient for isolation by n-hexane extraction, though absolute quantitative data (mg/g dry weight) have not been published; KA's very low aqueous solubility significantly limits its oral bioavailability without formulation strategies such as nanoencapsulation or lipid-based delivery.

Preparation & Dosage

- **Stem Bark n-Hexane Extract (Research Form)**: Koetjapic acid is isolated via n-hexane extraction and crystallization from dried stem bark; no standardized commercial supplement exists and no human-equivalent dose has been established.
- **Methanolic Fruit Peel Extract (Research Form)**: Prepared by maceration of dried peel in methanol; used in in vitro antioxidant and cytotoxicity assays at concentrations of 30–2000 µg/mL; not commercially available.
- **Traditional Stem Bark Decoction**: Bark is boiled in water and administered orally for diarrhea and fever in Filipino hilot and Southeast Asian folk medicine; no standardized preparation volume or concentration is documented.
- **Traditional Fruit Consumption**: Ripe and unripe fruit flesh consumed fresh or preserved; tannin and saponin content varies with ripeness and preparation method.
- **Effective Clinical Dose**: Entirely unestablished; no bioavailability data exist for KA in humans, and its very low aqueous solubility is a recognized barrier to systemic delivery.
- **Timing Notes**: No pharmacokinetic or pharmacodynamic timing guidance is available from any published study.

Synergy & Pairings

No formal synergy studies have been conducted for Sandoricum koetjape or koetjapic acid in combination with other ingredients; patent literature suggests KA may be combined with conventional chemotherapeutics as an anti-angiogenic adjunct, leveraging its VEGF suppression alongside cytotoxic agents, though no efficacy or safety data from such combinations exist. Tannin-rich peel extracts may theoretically synergize with other polyphenol antioxidants such as quercetin or ellagic acid through complementary radical scavenging mechanisms, but this remains entirely speculative. Within traditional Southeast Asian botanical formulations, santol bark is occasionally combined with other Meliaceae family members, though no documented pharmacological rationale for specific ingredient pairings has been scientifically validated.

Safety & Interactions

Human safety data for Sandoricum koetjape extracts or isolated koetjapic acid are entirely absent from the published literature, precluding the establishment of a maximum safe dose, no-observed-adverse-effect level, or tolerable upper intake for any population. In vitro cytotoxicity assays show that methanolic peel extract at 2000 µg/mL reduces Vero normal cell viability by 37.18%, indicating non-selective cytotoxic effects at high concentrations that raise concern about a narrow therapeutic window. No drug interaction studies exist; however, given KA's documented NF-κB upregulation and potential MAPK pathway interference, theoretical interactions with cytotoxic chemotherapeutics, immunosuppressants, and anti-inflammatory drugs cannot be excluded. Pregnancy and lactation guidance is unavailable; traditional use data do not provide sufficient safety characterization, and supplemental use outside of food consumption of the fruit is not recommended in the absence of clinical safety evaluation.